REFERENCES
- Boucher HW, Gra AH, Chiou CC, Walsh Ti. Newer Systemic AntifungalAgents: pharmacokinetics, safety and efficacy. Drugs 2004; 64 (18):1997–2020.
- Chandrasekar PH, Manavathu E. Voriconazol: a second-genera-tion triazole. Drugs Today 2001; 37(2):135–148.
- Chandrasekar PH, Manavathu EK. Caspofungin. Drugs Today 2002; 38(12): 829–846.
- Viscoli C. et al, Caspofungin (C) as first-Line therapy of invasive (IA) in haematological patients (pts) : a study of the EORTC Infections Diseases Group, oral presentation at TIMM (Trends In Medical Mycology), Torino, 2007
- Herbrecht R, Denning DW, Patterson TF, et al. Voriconazol ver-sus amphotericin B for primary therapy of invasive aspergil-N EngIJ Med 2002; 347:408–15.
- Denning D., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., Haas A., Ruhnke M., Lode H., Efficacy and safety of voricon-azole in the treatment of acute invasive aspergillosis, Clin In-fect Dis. 2002 Mar 1;34 (5):563–71
- Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39(11):1563–71.
- Wenzel R, Del Favoro A, Kibbler C et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J.Antimicrob.Chemother., 2005; 55 (3): 352–61.
- Marbaix S, Marciniak A, De Mees V et al. Cost-effectiveness of voriconazole compared with conventional amphotericin B in first Line treatment of invasive aspergillosis in Belgium. in Pre-sented at the ISPOR 6th European Congress, Barcelona, Spain. 2003.
- Jansen J, Kern W, Comely O et al. Economic evaluation of vori-conazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value in Health, 2006; 9 (1): 12–23.
- Jansen JP, Meis JF, Blijlevens NM et al. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Curr.Med.Res.Opin., 2005; 21 (10): 1535–154
- Walsh T.J. et al., Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia. N EngIJ Med 2004; 351:1391–402.
- Van Campenhout H., Marbaix S., Derde M-P, Annemans L., Vori-conazole treatment of invasive Aspergillosis : Real-world versus Health-Economic Model Results, Clin Drug Invest, 2008; 28 (8): 509–521.